MARKET

AGIO

AGIO

Agios
NASDAQ

Real-time Quotes | Nasdaq Last Sale

31.17
+1.37
+4.60%
After Hours: 31.17 0 0.00% 16:47 01/24 EST
OPEN
29.30
PREV CLOSE
29.80
HIGH
31.35
LOW
28.96
VOLUME
667.33K
TURNOVER
--
52 WEEK HIGH
62.16
52 WEEK LOW
28.96
MARKET CAP
1.69B
P/E (TTM)
-5.6170
1D
5D
1M
3M
1Y
5Y
Top Biotech Stocks for Q1 2022
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. ...
Investopedia · 6d ago
BRIEF-Agios Pharmaceuticals Expects To Hold 2022 Annual Meeting Of Stockholders On Tuesday, June 21, 2022 To Be Held Virtually Via Internet
reuters.com · 01/14 21:24
Seelaus Asset Management LLC Buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Sells ...
Investment company Seelaus Asset Management LLC (Current Portfolio) buys Merck Inc, Eagle Materials Inc, Coinbase Global Inc, Gentherm Inc, ABB, sells Zimmer Biomet Holdings Inc, KKR Inc, U.S.
GuruFocus.com · 01/10 18:38
Agios Pharma Lists 2022 Milestones
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February –   – Five Pivotal Clinical Trials are Planned and Ongoing in
Benzinga · 01/10 12:29
BRIEF-Agios Pharmaceuticals - Expects To Receive FDA Regulatory Decision For Mitapivat in February
reuters.com · 01/10 12:18
Agios Highlights 2022 Anticipated Milestones and Priorities to Drive Company’s Strategic Vision in Genetically Defined Diseases
– Company Expects to Receive FDA Regulatory Decision for Mitapivat as a Potential Treatment for Adults with PK Deficiency in February – – Five Pivotal Clinical Trials are Planned and Ongoing in Thalassemia, Sickle Cell Disease and Pediatric PK Deficiency –...
GlobeNewswire · 01/10 12:00
Top Small Cap Stocks for January 2022
These are the small cap stocks with the best value, fastest growth, and most momentum for January 2022.
Investopedia · 01/07 18:26
Some Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Estimates
The analysts covering Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) delivered a dose of negativity to shareholders today...
Simply Wall St. · 12/21/2021 09:27
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AGIO. Analyze the recent business situations of Agios through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

18.18%Strong Buy
36.36%Buy
36.36%Hold
9.09%Under-perform
0.00%Sell
Analyst Price Target
The average AGIO stock price target is 58.25 with a high estimate of 95.00 and a low estimate of 37.00.
High95.00
Average58.25
Low37.00
Current 31.17
EPS
Actual
Estimate
5.4112.4819.5526.62
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 259
Institutional Holdings: 66.47M
% Owned: 122.39%
Shares Outstanding: 54.31M
TypeInstitutionsShares
Increased
42
1.82M
New
19
333.33K
Decreased
67
5.73M
Sold Out
36
1.31M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Chairman/Director
David Schenkein
Chief Executive Officer/Director
Jacqualyn Fouse
Chief Financial Officer
Jonathan Biller
Chief Accounting Officer
T. J. Washburn
Chief Scientific Officer
Bruce Car
Other
Sarah Gheuens
Other
Richa Poddar
Lead Director/Independent Director
John Maraganore
Independent Director
Paul Clancy
Independent Director
Ian Clark
Independent Director
Kaye Foster
Independent Director
Maykin Ho
Independent Director
David Scadden
No Data
About AGIO
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Webull offers kinds of Agios Pharmaceuticals Inc stock information, including NASDAQ:AGIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AGIO stock methods without spending real money on the virtual paper trading platform.